Stock Ratings / Health Care / LSTA / financials

LTRN (42) TPST (44) GDTC (54) TVRD (40) ⌘ Pro Terminal →

Lisata Therapeutics Inc. (LSTA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.01 -4.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.00

Lisata Therapeutics Inc. (LSTA) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $10.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.00 (-1.04%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LSTA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY LSTA SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.06-2.8% Next Q

Q2 (-2Q)

Grade E$1.03-2.9% Next Q

Q3 (-1Q)

Grade E$1.00+1% Next Q

Current

Grade E$1.01-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LSTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LSTA currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.39) and Max Pain ($1.06) forces dealer call-delta covering toward $5.32.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LSTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LSTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LSTA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.0M

FY24

Rev $1.0M

FY25

Rev $170.0K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$170.0K	52%	-80%	-$17.0M	-$16.0M	-45%
FY 2024	$1.0M	52%	-80%	-$20.0M	-$19.4M	-45%
FY 2023	$1.0M	52%	-2570.8%	-$21.0M	-$20.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LSTA)

✓Walkthrough of LSTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LSTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.63%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.99H $1.09L $0.99C $1.01VOL 60.7K

RES: $1.68SUP: $0.96SMA50: $1.39SMA200: $2.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LSTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LSTA Butterfly Map → + Track LSTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LSTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LSTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LSTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LSTA)

Health Care Rank #901 of 1016 ⚔️ LTRN vs LSTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LSTA vs. LTRN, TPST, GDTC, TVRD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lisata Therapeutics Inc. (LSTA) ranks #901 by composite RQD confidence (32/100, grade E) and #890 by equity capitalization ($10.9M). Within this direct 5-issuer industry benchmark cohort, LSTA leads on earnings valuation at N/A trailing P/E, while LSTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GDTC currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with LSTA at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LSTA ACTIVE Lisata Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.72%	$10.9M	Benchmark Subject
LTRN Lantern Pharma Inc.	D-	42/100	—	—	-35.0%	-5.52%	$10.9M	/ltrn-vs-lsta →
TPST Tempest Therapeutics Inc.	D	44/100	—	—	-35.0%	-1.24%	$10.7M	/tpst-vs-lsta →
GDTC CytoMed Therapeutics Limited	D+	54/100	—	—	—	-3.68%	$10.7M	/gdtc-vs-lsta →
TVRD Tvardi Therapeutics Inc.	D-	40/100	—	—	-35.0%	-2.73%	$11.5M	/tvrd-vs-lsta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000320017

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lisata Therapeutics Inc. (LSTA) reported GAAP revenue of $170.0K (-83.0% vs. FY2024 revenue of $1.0M ) , GAAP net income of -$17.0M, operating cash flow of -$15.9M, and free cash flow of -$16.0M (+17.5% YoY). On the balance sheet, LSTA closed FY2025 with $17.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$170.0K	-$17.0M	-$15.9M	-$16.0M	$17.7M	—
FY2024 (FY)	2024-12-31	$1.0M	-$20.0M	-$19.4M	-$19.4M	$35.0M	—
FY2023 (FY)	2023-12-31	$0	-$21.0M	-$20.0M	-$20.0M	—	—

3. LSTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LSTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lisata Therapeutics Inc. (NASDAQ: LSTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.01 (-4.72% 1D, market cap $10.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LSTA ranks #901 in composite RQD confidence.

How does LSTA compare to LTRN and TPST in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LSTA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LTRN (Lantern Pharma Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M) and TPST (Tempest Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $10.7M). Among the 5-stock peer group, LSTA leads on earnings multiple (N/A) while LSTA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LSTA?

Per LSTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000320017), Lisata Therapeutics Inc. generated $170.0K in revenue (-83.0% YoY), -$17.0M in net income, and -$16.0M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LSTA trading relative to its 50-day, 200-day, and 52-week technical levels?

LSTA last traded at $1.01 (-4.72% on volume of 27,854 shares), positioning the stock -27.34% below its 50-day simple moving average ($1.39) and -66.22% below its 200-day simple moving average ($2.99). Across its 52-week range of $0.96 to $5.07, LSTA sits at the 1.2% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).

LSTA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Lisata Therapeutics Inc. (LSTA)?

In FY 2025 (10-K), LSTA converted $1.0M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: LSTA RQD Cockpit LSTA 12M Forecast LSTA Earnings & Move LSTA Dividends & DRIP LSTA Insiders & 13F LSTA Whale Options LSTA Profit Sankey LSTA News & Why